Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences, Inc.    GILD

Delayed Quote. Delayed  - 04/28 10:14:59 pm
97 USD   -3.69%
04/28DJGilead Reports Drop in Hepatitis C Drug Revenue -- Update
04/28DJGilead Reports Drop in Hepatitis C Drug Revenue
04/28 GILEAD SCIENCES : 1Q profit tumbles on slower hepatitis C drug sales
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Gilead Sciences, Inc. : FDA Panel Backs Gilead's HIV 'Quad' Medicine

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/11/2012 | 09:06pm CEST
   By Jennifer Corbett Dooren 
   Of  
 

A federal advisory panel Friday backed an experimental Gilead Sciences Inc. (GILD) HIV medicine known as the Quad.

The company is seeking approval from the Food and Drug Administration to market the product, which combines four active ingredients into one pill, meant to be taken once daily.

The medicine was reviewed on Friday by the agency's antiviral drugs advisory panel, which is made up of non-FDA medical experts. The panel voted 13 to 1 on a question that asked if the submitted clinical data supported approval of the drug. The panel vote amounts to a recommendation that the FDA approve the drug. The agency usually follows panel recommendations but isn't required to. The FDA is expected to make a decision by the end of August.

Quad is a combination of four active ingredients in one pill. It combines Gilead's double-drug Truvada, the drug elvitegravir and an agent that boosts blood levels of certain HIV drugs, cobicistat.

Gilead is hoping that the one-pill, once-daily Quad regimen will provide more convenience to HIV patients, many of whom now take multiple pills for treatment. Some analysts think it could become a blockbuster seller.

-By Jennifer Corbett Dooren; Dow Jones Newswires, 202-862-9294; jennifer.corbett@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
React to this article
Latest news on GILEAD SCIENCES, INC.
04/28DJGilead Reports Drop in Hepatitis C Drug Revenue -- Update
04/28DJGilead Reports Drop in Hepatitis C Drug Revenue
04/28 GILEAD SCIENCES : 1Q profit tumbles on slower hepatitis C drug sales
04/28 GILEAD SCIENCES INC : Results of Operations and Financial Condition, Financial S..
04/28 GILEAD SCIENCES : Announces Second Quarter 2016 Dividend
04/28 GILEAD SCIENCES : Announces First Quarter 2016 Financial Results
04/28 GILEAD SCIENCES : Announces Multiple Scientific Presentations Demonstrating Broa..
04/28DJAbbVie to Buy Cancer-Drug Maker for $5.8 Billion
04/26 GILEAD SCIENCES : secures EU approval for new HIV treatment
04/25GILEAD SCIENCES, INC. : quaterly earnings release
Advertisement
News chart
Full-screen chart
Income Statement Evolution
More Financials